Patronus Biotech Co., Ltd. announced that its three multi‑stage novel U‑VLP malaria vaccine candidates – LYB014, LYB017 and LYB027 – have been approved by the Bellberry Human Research Ethics Committee and will advance into a Phase I first‑in‑human (FIH) clinical trial (NCT07831226) in Australia, targeting both Plasmodium falciparum and Plasmodium vivax malaria.
Trial Initiation
| Item | Detail |
|---|---|
| Developer | Patronus Biotech Pte. Ltd. (Singapore, private) |
| Ethics Approval | Bellberry Human Research Ethics Committee (Australia) |
| Trial Phase | Phase I, first‑in‑human (FIH) |
| Trial Registration | NCT07831226 |
| Candidates | LYB014, LYB017, LYB027 – multi‑stage U‑VLP malaria vaccines |
| Indication | Prevention of malaria caused by P. falciparum and P. vivax |
| Trial Site | Nucleus Network Pty Ltd., Melbourne, Australia |
| First Subject Enrollment | Expected December 2026 |
Vaccine Profile & Mechanism of Action
- Platform: Novel U‑VLP (virus‑like particle) multi‑stage malaria vaccine platform designed to intercept the parasite at multiple points in its life cycle.
- LYB014: Targets three key life‑cycle stages of Plasmodium falciparum, the deadliest malaria species and the dominant cause of mortality in sub‑Saharan Africa.
- LYB017: Targets three key life‑cycle stages of Plasmodium vivax, the geographically most widespread species outside Africa and a major driver of relapsing malaria in Asia‑Pacific and the Americas.
- LYB027: A dual‑species candidate that simultaneously targets the three key life‑cycle stages of both P. falciparum and P. vivax, potentially offering broad‑spectrum coverage in a single product.
- Adjuvant: All candidates will be evaluated in combination with Patronus Biotech’s self‑developed A02 adjuvant, a novel liposomal adjuvant whose active ingredients are entirely synthetic – a design that supports manufacturing consistency and scalable GMP production.
- Strategic Rationale: Multi‑stage targeting may reduce the risk of parasite escape from single‑stage immunity, a known limitation of earlier malaria vaccine approaches.
Clinical Development – Phase I First‑in‑Human Trial
| Item | Detail |
|---|---|
| Trial Design | Randomized, double‑blind, controlled, dose‑escalation |
| Population | Healthy adult volunteers |
| Primary Assessments | Safety and immunogenicity |
| Immunogenicity Partner | Draper Laboratory, Department of Paediatrics, University of Oxford |
| Clinical Readouts | Data not yet disclosed |
The trial will be conducted at Nucleus Network Pty Ltd. in Melbourne, Australia, an experienced early‑phase clinical research unit. Immunogenicity analyses will be performed in collaboration with the Draper Laboratory at the University of Oxford, lending established academic immunology expertise to the program’s biomarker and antibody readouts.
Market Impact & Outlook
- Global Malaria Burden: Malaria remains one of the world’s deadliest infectious diseases, with WHO estimating roughly 250 million cases and more than 600,000 deaths annually, disproportionately affecting children in sub‑Saharan Africa – underscoring sustained demand for next‑generation vaccines.
- Differentiation vs. Existing Vaccines: Currently deployed malaria vaccines (RTS,S and R21) target a single pre‑erythrocytic stage of P. falciparum only; a multi‑stage, dual‑species U‑VLP approach addresses an unmet need for broader and potentially more durable protection, including against P. vivax, for which no licensed vaccine exists.
- Adjuvant Independence: The fully synthetic A02 liposomal adjuvant reduces reliance on constrained biological adjuvant supply chains, a strategic advantage for global scale‑up in a future public‑health rollout.
- Clinical Infrastructure: The combination of Nucleus Network’s Phase I execution capability and Oxford’s Draper Laboratory for immunogenicity analysis strengthens data credibility with regulators and potential partners.
- Next Milestones: First subject enrollment expected in December 2026; timing of safety and immunogenicity readouts not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding trial timelines, enrollment milestones, clinical outcomes, and the potential therapeutic profile of LYB014, LYB017, LYB027 and the A02 adjuvant. Actual results may differ materially due to risks including dose‑escalation findings, immunogenicity variability, regulatory requirements, and development timelines. Early‑phase candidates carry substantial uncertainty and may not proceed to licensure.-Fineline Info & Tech
